Connection
Jane Reusch to Dipeptidyl-Peptidase IV Inhibitors
This is a "connection" page, showing publications Jane Reusch has written about Dipeptidyl-Peptidase IV Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.576 |
|
|
|
-
Abushamat LA, Reusch JEB. Evolving Concepts of Type 2 Diabetes Management. Med Clin North Am. 2021 Nov; 105(6):955-966.
Score: 0.197
-
Scalzo RL, Rafferty D, Schauer I, Huebschmann AG, Cree-Green M, Reusch JEB, Regensteiner JG. Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. J Diabetes Complications. 2019 08; 33(8):561-566.
Score: 0.168
-
Keller AC, Knaub LA, Miller MW, Birdsey N, Klemm DJ, Reusch JE. Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki rat. J Cardiovasc Pharmacol. 2015 Feb; 65(2):137-47.
Score: 0.125
-
Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009 Oct; 25(10):2361-71.
Score: 0.086